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METHOD FOR ENHANCING PROTECTIVE 
CELLULAR RESPONSES TO GENOTOXIC 
STRESS IN SKIN 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a divisional of application Ser. No. 
09/765,129, ?led Jan. 18, 2001, now US. Pat. No. 6,552,050, 
Which is a divisional of application Ser. No. 09/452,617, ?led 
Dec. 1, 1999, now US. Pat. No. 6,337,065. This application 
claims bene?t of provisional patent application Ser. No. 
60/110,482 ?led Dec. 1, 1998. The entire disclosure of pro 
visional patent application Ser. No. 60/ 110,482 is hereby 
incorporated by reference. 
BACKGROUND 
1. Field of the Invention 
The invention is directed to methods and composition of 
using organic molecules termed pro-NAD agents capable of 
enhancing dermal and epidermal skin cell NAD content With 
a resulting enhancement of DNA repair and other protective 
responses to genotoxic stress in skin. 
2. Description of the Background 
The present application relates to methods and composi 
tions capable of modulating and upregulating the cellular 
nicotinamide-adenine-dinucleotide (NAD) content by the 
topical application of chemical agents for the purpose of 
enhancing natural protective responses of skin cells to DNA 
damage. The methods and compositions are effective for the 
prevention and treatment of skin deterioration that results 
from DNA damage to cells of the skin. The symptoms of such 
skin deterioration are many and typically include the loss of 
moisture, ?ne lines, deep lines, Wrinkles, and loss of elasticity 
as Well as atrophic sclerosis and other blemishes of skin. Skin 
deteriorates With age as a natural consequence of prolonged 
exposure to internal and external factors. Internal deteriora 
tion factors include natural metabolic byproducts such as free 
radicals Which cause the aging of all tissues. External dete 
rioration factors include ioniZing radiation such as sunlight 
and chemical insults such as pollution and cigarette smoke. In 
theory, skin care methods and compositions should inhibit, or 
sloW the process of skin deterioration by counteracting these 
internal and external factors. Unfortunately, current methods 
and compositions for skin care are generally reactive rather 
than proactive. That is, current methods and compositions 
reduce or obscure the signs of aging but have minimal or no 
effect on the underlying progressive and cumulative bio 
chemical processes that cause skin deterioration. It is there 
fore desirable to have a skin care method and composition 
Which not only reduce the symptoms of deterioration but also 
treat the underlying causes of skin deterioration in such a Way 
that deterioration can actually be retarded. To understand the 
limitations of current methods and compositions, it is neces 
sary to understand the function and structure of the skin and 
the mechanisms of skin deterioration. 
At ten pounds, the skin is the largest organ in the body. FIG. 
1 shoWs a diagram of skin marking the location of the tWo 
major cell types present in skin, namely ?broblasts located in 
the dermal layer of the skin and keratinocytes located in the 
epidermal layer of the skin. The skin provides the ?rst line of 
defense betWeen the body’ s interior and harmful environmen 
tal insults by Well established physical and biochemical 
mechanisms. Physical protection mechanisms include the 
relatively impermeable barrier the skin provides. The skin 
can, to some extent, repel and absorb insults such as chemi 
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cals and ultraviolet light so that While the skin may be dam 
aged, the underlying tissue is preserved. Biochemical mecha 
nisms include the innate and acquired immune systems. 
Microbiological pathogens are repelled by immune responses 
at the epidermal level involving Langerhans cells, kerati 
nocytes, cytokines, polynuclear cells, endothelial cells, mast 
cells, and lymphocytes. 
Structurally, the skin comprises epithelial tissue (the epi 
dermis) in the outer layer and beneath it, connective tissue 
(the dermis), and beneath that, the fatty tissue (hypodermis). 
The epidermis is not vasculariZed and regenerates every four 
to six Weeks. Its primary function is to maintain the body’s 
skin integrity, acting as a physical barrier to toxic agents, dirt, 
bacteria, microorganisms, and physical insults. The dermis is 
beneath the epidermis and functions by providing strength, 
support, blood, and oxygen to the skin. The principal cell 
components of the dermis are ?broblasts although it also 
contains sWeat glands, sebaceous glands, hair follicles, and 
small fat cells. Hypodermis, also knoWn as the super?cial 
fascia, attaches the dermis to the underlaying structures. Its 
function is to promote an ongoing blood supply to the dermis 
for regeneration. 
The mechanisms of skin deterioration involve a gradual 
and progressive process that beings from birth. Internal fac 
tors that contribute to skin aging include toxic metabolic 
byproducts, autoimmune diseases, and genetic predisposi 
tion. The consequences of internal deterioration can be 
observed over the entire body from the skin to the internal 
organs. While the mechanisms of internal deterioration are 
not completely understood, somatic mutation has been shoWn 
to be a contributing factor. Under the somatic mutation 
theory, cells gradually lose their youthful characteristics and 
their capacity to divide by the accumulation of mutations 
(errors) in their genetic code. These mutations may be caused 
by free radicals or alkylating agents generated in metabolism 
that lead to unrepaired DNA damage. Over time, mutations 
accumulate in the body until the cell can no longer divide or 
produce functional proteins. 
External factors such as chemical and physical agents in 
the environment can also cause DNA damage that leads to 
skin deterioration. The external factors include sunlight, pol 
lution, and ingested chemicals from smoking or from food. 
Deterioration of skin leads to changes in dermal thickness 
and elasticity due to increased crosslinking of collagen. Epi 
dermal regeneration increases in activity While metabolism, 
sWeat glands, and vasculariZation, all decrease in activity. The 
damage from internal and external factors is progressive and 
cumulative and results in the appearance of deterioration 
associated With aged skin. 
Related to the somatic mutation theory, both internal and 
external factors contribute to oxidative stress, Which in turn 
results in DNA damage. In humans, oxidative stress and DNA 
damage is caused by factors such as hyperbaric oxygen, 
gamma radiation, ultraviolet radiation, oZone, peroxides, free 
radicals, alkylating agents, and redox cycling drugs. While 
total oxidative stress and DNA damage may be reduced by 
living in a loW pollution environment and avoiding sunlight, 
they cannot be eliminated. Some factors like ioniZing radia 
tion are present in all environments at a loW level and other 
factors are byproducts of metabolism and cannot be totally 
eliminated. Further, urban environments have high levels of 
ground level pollution from a variety of sources that are not 
likely to be reduced in the near future. HoWever, While DNA 
damage cannot be avoided, not all DNA damage leads to 
mutations. 
DNA damage does not necessarily lead to mutation 
because a normal cell contains diverse and effective systems 
US 7,425,319 B2 
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for repairing damaged DNA. There are at least 50, and pos 
sibly more than 100 genes involved in DNA repair. The 
importance of good DNA repair in retarding skin deteriora 
tion is most noticeable in patients that suffer from DNA repair 
defects such as xeroderrna pigmentosum @(P). XP have early 
and accelerated skin deterioration, clearly demonstrating the 
importance of DNA repair to reducing deterioration of the 
skin. In addition to DNA repair, a normal cell also has systems 
that invoke “programmed cell deat ” by a process termed 
apoptosis. The process of apoptosis effectively “erases” cells 
damaged beyond the point of repair. These natural defense 
mechanisms of the skin have been ignored by current meth 
ods of preventing skin deterioration. 
Many creams, lotions, bath oils, ointments, pastes, cleans 
ers, covers, and poWders claim to be effective in preventing 
skin deterioration. HoWever, all current methods and compo 
sitions have severe disadvantages in that they are limited in 
their ability to retard skin deterioration. Mo st over the counter 
skin care products soften deteriorated skin or otherWise 
reduce the symptoms of deteriorated skin With no effect on 
the underlying biochemical processes involved in deteriora 
tion. Many existing skin care products and cosmetics function 
by providing moisture to the skin, preventing moisture loss, 
or providing cover to obscure the visible signs of deteriora 
tion. While traditional cosmetics may have effects on appear 
ance, these effects are evanescent and any apparent improve 
ment disappears as soon as the product use is discontinued. 
Further, traditional cosmetics’ effectiveness decrease upon 
exposure to moisture and thus cosmetics must be reapplied 
after exercise, sWimming, or any other exposure to moisture. 
Some cosmetics contain metals (e.g., iron and copper) Which 
may actually increase skin levels of free radical formation and 
possibly promote deterioration. As the use of such products 
does not prevent deterioration, more and more of the product 
is needed as time progresses to obscure the increasing severe 
condition of the underlying skin. 
Another method for treating aging skin is the use of alpha 
hydroxy acids (AHA) such as lactic acid, citric acid, glycolic 
acid, malic acids; beta hydroxy acids (BHA) such as salicylic 
acid; and retinoids (e.g. tretinoin (retin A), retinol and reti 
nal), as exfoliants. These agents help remove the uppermost 
layer of skin to expose the more youthful underlying skin. 
HoWever, there is a danger that by removing the outer layer of 
skin, AHA, BHA and retinoids can compromise the important 
barrier function of skin. It is possible that the use of these 
exfoliants may accelerate skin aging by removing the protec 
tive outer layer of skin. Exfoliants and other ingredients may 
also increase the skin’s sensitivity to environmental condi 
tions such as sunlight, Wind, cold temperature and dry air, or 
to chemical agents such as antigens, or may exacerbate the 
irritation attributable to a pre-existing skin disease. Another 
disadvantage of AHA, BHA and retinoids is that these com 
pounds are potential skin irritants Which can induce side 
effects such as sore, red skin. 
Another popular method for skin treatment is the use of 
sunblocks. Sunblock (i.e., sunscreen) refers to any chemical 
that When applied to the skin, reduces the amount of UV light 
that reaches the skin. By preventing UV absorptions that 
cause genomic mutations, sunblocks can decrease and retard 
skin deterioration. Sunblocks Were originally designed to 
prevent sunburn (also knoWn as erythema), an acute reaction 
to overexposure to the sun. The strength of sunblocks is 
measured by the SPF index (Sun Protection Factor). An SPF 
value of l 5, for example, Will provide 15 times the protection 
of bare skin to sunburns. HoWever, it should be noted that the 
SPF values, Which measures resistance to sunburn, cannot be 
extrapolated to photoaging protection, Which is caused by 
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constant loW level environmental insults. That is, a sunblock 
With an SPF factor of 15 Will not reduce photoaging 15 fold. 
There is also a danger that chemicals in some sunblocks Will 
increase DNA damage and contribute to skin deterioration. 
Finally, every major class of sunblock has been linked to skin 
allergies. 
Finally, there are agents that are physical blends of existing 
agents. A physical blend is a mixture of tWo or more chemi 
cals. Physical blends can be mixed poWders, mixed solutions, 
mixed emulsions, mixed colloidal solutions, particles in solu 
tions, and the like. An example of a physical blend may be a 
covering or coloring cosmetic mixed With a sunblock (tita 
nium dioxide) and a hydroxy acid. 
In summary, current methods of skin treatment are mostly 
reactive in that they treat the symptoms of deterioration after 
the damage is done. Current skin treatment methods do not 
reverse damage to the dermal tissue. There is a need for 
topical skin care products that are proactive rather than reac 
tive. A proactive product is one that Will assist the skin in 
resisting DNA damage by either preventing damage or assist 
ing in repair of any damage. 
SUMMARY OF THE INVENTION 
The present invention overcomes many of the limitations, 
problems and disadvantages associated With current strate 
gies and designs for preventing skin deterioration and pro 
vides methods and composition for the treatment of skin 
deterioration. 
One object of the invention is directed to a method and 
composition for treating skin to prevent and sloW the deterio 
ration process. 
It is another objective of the invention to provide a method 
to retard deterioration of the skin by enhancing the skin’s 
natural DNA repair mechanism. 
It is another object of the invention to provide a method for 
the sustained release of pro-NAD agents to skin cells. 
Another object of the invention is directed to a composition 
for topical application comprising one or more pro-NAD 
agent that promote cellular DNA repair. 
One embodiment of the invention is directed to a pharma 
ceutical composition for a subject in need of an elevation of 
intracellular NAD content. The pharmaceutical composition 
comprises a pro-NAD agent and a pharmaceutically accept 
able carrier. The pro -NAD agent is present in the pharmaceu 
tical composition at a concentration su?icient to elevate intra 
cellular NAD in the subject. The pharmaceutical composition 
maybe adapted for topical administration to the skin. Adap 
tation may included the inclusion of a pharmaceutically 
acceptable carrier Which is suitable for use in topical appli 
cations. 
The pro-NAD agents of the invention may comprise one or 
more compounds With the folloWing formula: 
Where R1 is a hydrogen or any chemical group that can be 
enZymatically or chemically removed to generate nicotinic 
acid folloWing administration to said subject. A chemical 
group is any chemical molecule such as, for example, any 
US 7,425,319 B2 
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branched or unbranched (straight) alkane, alkene, or alkyne 
group. In a preferred embodiment, the chemical group is a 
group such as an ester, that can be removed by an esterase 
following the administration of the pharmaceutical composi 
tion to the subject. Preferably, the esterase is an intracellular 
esterase such that the chemical group is not removed until the 
pro-NAD agent is inside a cell. 
In a preferred embodiment, R1 is an unbranched or 
branched chain alkane, alkene or alkyne of 1 carbon to about 
30 carbon atoms, such as, for example betWeen about 14 and 
about 22 carbons. Rl may also contain one or more functional 
groups. A functional group is an atom or group of atoms 
acting as a unit, that has replaced a hydrogen atom in a 
hydrocarbon molecule and Whose presence imparts charac 
teristic properties to a molecule. Examples of functional 
groups that can be used include thiol, alcohol, amine, car 
boxylic acid, onium, carboxylic anhydride, carboxylic ester, 
acyl halide, amide, nitrile, aldehyde, ketone, imines, ethers, 
sul?de, halide, nitro, nitroso, aZides, diaZo, and a combina 
tion of these groups. 
In a preferred embodiment, Rl may be a chemical group 
that changes the log PO/W of said pro-NAD agent to betWeen 
about 5 to about 20. 
In a preferred embodiment, the pro-NAD agent has a log 
PO/W range betWeen about 5 to about 20. More preferably, the 
pro-NAD agent has a log PO/W range betWeen about 10 to 
about 15. 
For example, the pro -NAD agent may be methylnicotinate, 
ethylnicotinate, butylnicotinate, hexylnicotinate, octylnicoti 
nate, tetradecylnicotinate, octadecylnicotinate or a combina 
tion of these chemicals. A combination may be, for example, 
at least one chemical selected from the group consisting of 
methylnicotinate, ethylnicotinate, butylnicotinate, hexylni 
cotinate, octylnicotinate and at least one chemical selected 
from the group consisting of tetradecylnicotinate and octade 
cylnicotinate. 
Alternatively, the pro-NAD agent may comprise one or 
more compounds With the folloWing formula: 
% 
\N 
Where R2 is a hydrogen or a chemical group that can be 
enZymatically or chemically removed to generate nicotina 
mide after the pharmaceutical composition is administered. 
For example, R2 may be a carboxylic acid containing an 
alkane, alkene or alkyne of about 1 to about 30 carbon atoms. 
Preferably, R2 is a carboxylic acid containing an alkane R 
group With betWeen 14 and 22 carbons. In addition R2 also 
contains one or more functional groups. The functional group 
may be, for example, thiol, alcohol, amine, carboxylic acid, 
onium, carboxylic anhydride, carboxylic ester, acyl halide, 
amide, nitrile, aldehyde, ketone, imines, ethers, sul?de, 
halide, nitro, nitroso, aZides, or diaZo. Preferred functional 
groups include thiol, alcohol, amine, and carboxylic acid 
groups. R2 may also have more than one functional group. 
Further, R2 may be any chemical group that changes the log 
PO/W of said pro-NAD agent to betWeen about 5 to about 20. 
Preferably, the pro-NAD agent has a log PO/W range betWeen 
about 5 to about 20. More preferably, the pro-NAD agent has 
a log PO/W range betWeen about 10 to about 15. 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
6 
The pharmaceutical composition of the invention may 
have a pro-NAD agent concentration that is betWeen about 
0.001% to about 10% by Weight. Preferably, the pro-NAD 
agent is betWeen about 0.01% and about 3% by Weight. The 
pharmaceutical composition may further comprise an 
optional agent such as, for example, antioxidants, sunscreens, 
vitamins, a pH stabiliZer, or a combination of these agents. 
It is understood that the pharmaceutical composition of the 
invention may be used for treating a subject. The subject is an 
animal. The animal may be a unicellular or a multicellular 
animal such as, for example, a mammal. Further, the mammal 
may be a human. The subject may also be a cultured cell 
population, a cultured cell line, an egg, a sperm or a Zygote. 
Another embodiment of the invention is directed to a 
method for treating or for sloWing skin deterioration. In the 
method, a pharmaceutical composition of the invention may 
be administered to a subject to treat, sloW or reverse skin 
deterioration in the subject. Preferably, the method Will 
increase the skin cell intracellular NAD concentration by at 
least about 50% over an untreated subject. More preferably, 
the method Will increase the intracellular NAD concentration 
by an even greater amount such as, for example, by 100% over 
an untreated subject. It is understood that skin cell in this 
application refers to ?broblasts and/or keratinocytes. The 
administration may be applied topically, intradermally or 
subcutaneously. Topical administration may be via dermal 
patch or sloW release mechanism to the layer of skin of the 
mammal. In addition, the administration may be oral or 
parenteral. 
Another embodiment of the invention is directed to a pro 
cess for achieving transderrnal delivery of a pro-NAD agent. 
In the process, an effective amount of a topical composition 
comprising an effective amount of one or more pro-NAD 
agent is applied to the skin of a subject. The pro-NAD agent 
used in this process may be any pro-NAD agent discussed in 
this application. 
Another embodiment of the invention is directed to a pro 
cess for reducing the cytotoxic effects of DNA damage in the 
skin of a mammal by enhancing or elevating one or more skin 
cell intracellular proteins. The skin cells are the ?broblasts 
and/or keratinocytes in the skin. The process comprises 
applying to a layer of skin of the mammal an effective amount 
of a pharmaceutical composition of the invention. The intra 
cellular protein may be p53. Alternatively, the intracellular 
protein may be PARP-l, PARP-2, PARP-3, tankyrase, 
V-PARP and telomerase. 
Another embodiment of the invention is directed to a 
method for treating skin in order to inhibit skin deterioration 
due to UV exposure. In the method, a pharmaceutical com 
position of the invention is applied to the skin at a time 
suf?ciently close to the time of UV exposure to inhibit UV 
induced damage to the skin. The pharmaceutical composition 
may be applied before UV exposure. Alternatively, the phar 
maceutical composition maybe applied after UV exposure. 
The time of application may be for example, less than 1 hour, 
less than 2 hour, less than 6 hour, less than 12 hour or less than 
1 day before UV exposure. Alternatively, the time of appli 
cation may be, for example, less than 5 minutes, less than 10 
minutes, less than 20 minutes, less than 1 hour, less than 2 
hours, less than 6 hours, less than 12 hours, less than 1 day, 
less than 2 days, or less than 5 days after UV exposure. 
Other embodiments and advantages of the invention are set 
forth, in part, in the description Which folloWs and, in part, 
Will be obvious from this description and understood by the 
skilled artisan practicing this invention. 









